Archive
Wade Emmert
HIPAA Update – Q1 2026
The first quarter of 2026 has brought a wave of regulatory activity, enforcement actions, and emerging compliance challenges under HIPAA. From a proposed overhaul of the…
Wade’s Health Law Highlights for March 24, 2026
The OIG issued a favorable advisory opinion allowing a medical device manufacturer to subsidize Medicare cost-sharing obligations for patients enrolled in a clinical trial testing an…
Wade’s Health Law Highlights for March 17, 2026
Aetna Inc. agreed to pay $117,700,000 to resolve allegations that it violated the False Claims Act by submitting inaccurate diagnosis codes for Medicare Advantage enrollees to…
Wade’s Health Law Highlights for March 10, 2026
The Office of Inspector General approved an arrangement allowing a management company affiliated with urgent care centers to establish an independent clinical laboratory without violating the…
Wade’s Health Law Highlights for March 3, 2026
The FDA issued a warning about Generation 1 Purge Cassettes in Johnson & Johnson MedTech’s Impella heart pumps after the components were linked to 4 injuries.…
No, You Can’t Just Not Take Medicare: What Every Chiropractor Needs to Know
A growing number of chiropractors are moving away from insurance panels in favor of cash-pay practice models built around direct-pay patient relationships. The appeal is understandable—simplified…
Wade’s Health Law Highlights for February 24, 2026
The DOJ Antitrust Division awarded its first whistleblower payout of $1 million to an individual who exposed a bid rigging and fraud scheme at EBlock Corp.’s…
Wade’s Health Law Highlights for February 17, 2026
Texas Attorney has launched an investigation into what he describes as potentially the largest data breach in U.S. history, issuing Civil Investigative Demands to Blue Cross…
Wade’s Health Law Highlights for February 10, 2026
Ambulatory surgery centers now treat patients with conditions far beyond their original design parameters. ASCs increasingly care for patients with diabetes, obesity, cardiovascular disease, arrhythmias, anticoagulation…
Wade’s Health Law Highlights for February 3, 2026
Reference product exclusivity grants biological products 12 years of market protection under the Biologics Price Competition and Innovation Act, during which the FDA will not approve…